Compare GME & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GME | RDY |
|---|---|---|
| Founded | 1996 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Electronics Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 11.6B |
| IPO Year | 2002 | N/A |
| Metric | GME | RDY |
|---|---|---|
| Price | $22.07 | $14.09 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $13.50 | ★ $16.90 |
| AVG Volume (30 Days) | ★ 6.3M | 969.1K |
| Earning Date | 12-09-2025 | 01-22-2026 |
| Dividend Yield | N/A | ★ 0.51% |
| EPS Growth | ★ 387.37 | 9.95 |
| EPS | ★ 0.83 | 0.79 |
| Revenue | $3,808,200,000.00 | ★ $3,851,623,984.00 |
| Revenue This Year | $9.86 | $6.16 |
| Revenue Next Year | $2.83 | $2.57 |
| P/E Ratio | $25.66 | ★ $17.83 |
| Revenue Growth | N/A | ★ 14.10 |
| 52 Week Low | $19.93 | $12.26 |
| 52 Week High | $35.81 | $16.17 |
| Indicator | GME | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 49.71 | 53.57 |
| Support Level | $21.50 | $13.97 |
| Resistance Level | $24.00 | $14.16 |
| Average True Range (ATR) | 0.83 | 0.16 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 49.46 | 78.76 |
GameStop Corp is a U.S. multichannel video game, consumer electronics, and services retailer. The company operates across Europe, Canada, Australia, and the United States. The company sells new and second-hand video game hardware, physical and digital video game software, and video game accessories, mainly through GameStop, EB Games, and Micromania stores and international e-commerce sites. The majority of sales are from the United States. The company categorizes its products in three categories: Hardware and accessories, Software, and Collectibles. The company generates the majority of its revenue from the sale of Hardware and accessories products.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.